Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive Thermogenesis Driving Catch-Up Fat Is Associated With Increased Muscle Type 3 and Decreased Hepatic Type 1 Iodothyronine Deiodinase Activities: A Functional and Proteomic Study.

Frontiers in endocrinology·2021
Same author

Thyroid function in preterm infants and neurodevelopment at 2 years.

Archives of disease in childhood. Fetal and neonatal edition·2020
Same author

Unique near-complete deletion of GLI2 in a patient with combined pituitary hormone deficiency and post-axial polydactyly.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2019
Same author

The <i>In Vitro</i> Functional Impairment of Thyroid Hormone Receptor Alpha 1 Isoform Mutants Is Mainly Dictated by Reduced Ligand Sensitivity.

Thyroid : official journal of the American Thyroid Association·2019
Same author

<i>In Vitro</i> Characterization of Human, Mouse, and Zebrafish MCT8 Orthologues.

Thyroid : official journal of the American Thyroid Association·2019
Same author

Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.

The lancet. Diabetes & endocrinology·2019

Related Experiment Video

Updated: Jul 19, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Transient hypothyroxinaemia in preterm infants.

Fiona L R Williams1, Theo J Visser, Robert Hume

  • 1Community Health Sciences, University of Dundee, Dundee, Scotland, UK.

Early Human Development
|November 3, 2006
PubMed
Summary

Transient hypothyroxinaemia, common in preterm infants, involves temporary low thyroid hormones (T4, T3) and can cause neurodevelopmental deficits. Treatment should focus on correcting underlying causes and be limited to clinical trials for affected infants.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Related Experiment Videos

Last Updated: Jul 19, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Area of Science:

  • Neonatal endocrinology
  • Neurodevelopmental biology

Background:

  • Thyroid hormones are crucial for normal brain development.
  • Transient hypothyroxinaemia, characterized by temporary low T4 and T3 with normal/low TSH, is frequent in preterm infants.
  • Low T4 levels in preterm infants correlate with lasting cognitive and motor deficits.

Purpose of the Study:

  • To investigate the significance of low T4 levels in preterm infants.
  • To evaluate the efficacy of thyroid hormone substitution therapy.
  • To determine if low T4 is an epiphenomenon or a treatable condition.

Main Methods:

  • Review of existing thyroid hormone substitution trials.
  • Analysis of multifactorial causes of transient hypothyroxinaemia.
  • Assessment of therapeutic strategies targeting correctable components.

Main Results:

  • Current thyroid hormone substitution trials are underpowered with inconsistent results.
  • The etiology of transient hypothyroxinaemia is multifactorial.
  • Therapeutic strategies focus on correcting iodine deficiency, managing non-thyroidal illnesses, and addressing drug interferences with the thyroid axis.

Conclusions:

  • Thyroid hormone substitution therapy in preterm infants should be reserved for clinical trials.
  • Therapy should be administered only to infants with confirmed hypothyroxinaemia.
  • Further research is needed to clarify the role and optimal management of transient hypothyroxinaemia.